HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Looks To Maximize Opportunity As China Builds Drug Standards

This article was originally published in PharmAsia News

Executive Summary

A relationship initiated in the wake of a fatal heparin scandal between USP and the China Pharmacopeia Commission is going strong, presenting opportunities for companies like Sanofi and China’s Tasly as the Middle Kingdom gets set to expand drug standards.

You may also be interested in...



After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration

BEIJING - After signing an agreement on cooperation with China's Center for Disease Control and Prevention in the wake of a series of contaminated drug and food scandals, leaders of the U.S. Pharmacopeial Convention are working to develop new tests that could be used to safeguard the global supply chain

U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States

BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals

COVID And Beyond: China Urged To Address Chronic Disease, Improve Access

Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.

Topics

Related Companies

UsernamePublicRestriction

Register

LL088099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel